Study of a new immune therapy for advanced solid tumors with MAGE-A1
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This trial tests a new drug that helps your immune system find and attack cancer cells that have a specific marker (MAGE-A1). It's for people with advanced solid tumors who have run out of standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor (like esophageal, liver, head/neck, or lung cancer) that has spread and no longer responds to standard treatments.
- Your tumor tests positive for a protein called MAGE-A1.
- You carry the HLA-A*02:01 genetic marker (a blood test can check this).
- You have at least one tumor that can be measured on scans.
- You are generally able to care for yourself and are not bedridden (ECOG 0-1).
- You have adequate organ function and a life expectancy of at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
This trial tests a new type of immune therapy called MAGE-A4-directed TCR-T. It uses your own immune cells (T cells) that are modified to find and attack cancer cells that have a specific protein (MAGE-A4). It is for people with advanced solid tumors who have already tried other treatments.
This study tests a new type of immune cell therapy that seeks out and attacks cancer cells. It is for people with advanced solid tumors who have not improved with standard treatments and whose tumors show certain markers.
This trial tests a new drug, MRG006A, for people with advanced solid tumors, especially liver cancer. It aims to see if the drug is safe and effective by targeting a protein called GPC3 found on some cancer cells.
This early-phase trial tests whether combining a lab-made CAR-DC cancer vaccine with immune checkpoint medicines can shrink tumors that have specific genetic changes. It’s meant for people with advanced or returning (relapsed) solid tumors or certain lymphomas that match required tumor markers.
This trial tests a new cell therapy called YK1101 for people with advanced solid tumors that have not responded to standard treatment. It targets a specific protein (MAGE-A4) on cancer cells and requires a matching genetic type called HLA-A*11:01.
Hear when a new Lung Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.